Slide 1: 2010 Preliminary results, Outlook for 2011
Conference call, 9 February 2011 2010 Preliminaryy results Outlook for 2011
Slide 2: 2010 Highlights
2010 HIGHLIGHTS • Revenue € 728.1 million, down 2.6%, international sales down 1.2% • Operating income (EBIT) € 154.8 million, down 4.6% • Net Income € 108.6 million, down 1.8% • Silodosin (Urorec®/Silodyx™) approved in Europe and launched in a number of countries • Carbaglu® (carglumic acid) approv
Slide 3: Composition of Revenue
COMPOSITION OF REVENUE (million Euro) 2010 2009 Change % Italyy 197.0 210.6 ( ) (6.5) France 139.9 162.4 (13.8) Germany 63.3 65.8 (3.8) Portugal 36 3 36.3 36 8 36.8 (1 5) (1.5) Spain 29.6 30.9 (4.0) United Kingdom 9.9 15.1 (34.9) Other Western European countries 16.9 15.6 8.1 Russia, Turkey, other C
Slide 4: Geographical Breakdown of Pharmaceutical Revenue
GEOGRAPHICAL BREAKDOWN OF PHARMACEUTICAL REVENUE Portugal 5.2% Spain 4.2% Germany 9.0% UK 1.4% Other W. European countries 2.4% Russia Turkey Russia, Turkey, other CEE 10 10.0% 0% France 19.9% Other international sales 19.8% Italy 28.1% Data: Full year 2010 Pharmaceutical revenue € 702.3 m 3
Slide 5: Main Product Sales
MAIN PRODUCT SALES (million Euro) 2010 2009 Change % Zanidip® (lercanidipine) 148 7 148.7 214.9 (30.8) Zanipress® (lercanidipine+enalapril) 31.7 20.8 52.5 Other corporate products 54.9 37.1 48.0 Orphan drugs 58.8 48.9 20.1 4
Slide 6: Composition of Revenue by Business
COMPOSITION OF REVENUE BY BUSINESS Zanipress 4.4% Other corporate products 7.5% Zanidip 20.4% Orphan drugs 8 8.1% 1% Pharmaceutical chemicals 3.5% Local product portfolios 51.6% Other revenue 4.5% Entact®/Elopram® 6% (escitalopram/citalopram) - Italy Peptazol® (pantoprazole) – Italy 3% Methadone – F
Slide 7: Full Year 2010 Results
FULL YEAR 2010 RESULTS (million Euro) 2010 2009 Change % Revenue 728.1 747.5 (2.6) Gross Profit 488.1 511.9 (4.7) as % of revenue 67.0 68.5 SG&A Expenses 260.5 267.4 (2.6) as % of revenue 35.7 35.7 R&D & Expenses pe ses 68.8 69.4 69 (0.9) (0 9) as % of revenue 9.5 9.3 Other Income (Expense), net (3.
Slide 8: Financial Projections 2011 Targets
FINANCIAL PROJECTIONS 2011 TARGETS 2010 2011 Actual Targets (million Euro) Revenue 728.1 ~ 750 Operating income (EBIT) 154.8 ~ 160 Net Income 108.6 ~ 110 Based on existing business, no new acquisitions included. 7
Slide 9: Company declarations, disclaimers and profile
Company declarations, disclaimers and profile DECLARATION BY THE MANAGER RESPONSIBLE FOR PREPARING THE COMPANY’S FINANCIAL REPORTS The manager responsible for preparing the company’s financial reports Fritz Squindo declares, pursuant to paragraph 2 of Article 154-bis of the Consolidated Law on Finan